Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Medipal Group to Determine Profitability with Each Customer: Next President Shuichi Watanabe
March 2, 2012
-
BUSINESS DSP to Acquire Boston Biomedical, US Bioventure Specializing in Oncology
March 1, 2012
-
BUSINESS Pfizer Japan to Set Up Rare Disease Division
February 29, 2012
-
REGULATORY MHLW Conducts Hearing on Distribution Improvement with Drug Manufacturers
February 28, 2012
-
REGULATORY Next 5-Year Strategy Calls for Boost to Japanese“Rising Sun”Seed Development
February 27, 2012
-
REGULATORY PAFSC’s First Committee on Drugs Recommends Approval for Eli Lilly’s Once-Weekly GLP-1 Receptor Agonist
February 27, 2012
-
BUSINESS Diabetes Treatments: Their Development and Market (2)
February 27, 2012
-
BUSINESS Daiichi Sankyo and Terumo Codevelop Intradermal Vaccine
February 24, 2012
-
REGULATORY MEXT to Make Drug Education Compulsory at Junior High Schools from FY2012
February 23, 2012
-
BUSINESS Novo Nordisk President Says “Current Pipeline Most Substantial”
February 22, 2012
-
ORGANIZATION Japan Pharmaceutical Political Association Chairman Kumakura to Focus on Resolving Price Difference
February 21, 2012
-
REGULATORY MHLW Issues Improvement Order to Janssen Pharmaceutical for GMP Violation
February 20, 2012
-
BUSINESS Diabetes Treatments: Their Development and Market
February 20, 2012
-
BUSINESS 6 SGLT-2 Inhibitors in Final Development Stage, Applications Expected in 2013
February 17, 2012
-
BUSINESS Sanofi-aventis Nichi-Iko Obtains Approval for Allegra Generic Ahead of Competitors
February 16, 2012
-
REGULATORY Over 30 Companies Target Nu-lotan Generic Listing in June, 60% Pricing Rule to Apply
February 15, 2012
-
BUSINESS Dispensing Pharmacies Set to Reopen in Disaster-Hit Areas
February 14, 2012
-
REGULATORY Healthcare Providers, Bill Payers in Face-Off Over Additional Premiums for Generic Name Prescriptions
February 13, 2012
-
BUSINESS Nichi-Iko to Shift Back Priority to Its Own Generics from Transferred Long-Listed Products
February 13, 2012
-
ORGANIZATION NPhA Compiles Draft Proposal for Mutual Understanding to Improve Distribution
February 10, 2012
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…